NYLIM
CERE

New York Life Investment Management’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

New York Life Investment Management’s Portfolio CERE Stock Details CERE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-178,765
Closed -$7.31M – 886
2024
Q2 		$7.31M Buy
178,765
+32,923
+23% +$1.37M 0.07% 243
2024
Q1 		$6.16M Buy
+145,842
New +$6.13M 0.06% 281

Other funds holding CERE

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return

New York Life Investment Management's CERE Position: Q3 2024 in Review

New York Life Investment Management sold out of Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q3 2024, closing a stake of 178,765 shares — an estimated $7.31M sold.

New York Life Investment Management first reported a position in CERE in Q1 2024 and held it in 2 quarters. The position peaked at $7.31M in Q2 2024. 2 funds tracked by Wall St. Rank hold CERE as of Q3 2024.

  • New York Life Investment Management reported no remaining Cerevel Therapeutics Holdings, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
  • New York Life Investment Management sold 178,765 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q3 2024, an estimated $7.31M.
  • New York Life Investment Management first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q1 2024 and held it in 2 quarters.
  • New York Life Investment Management's Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $7.31M in Q2 2024.
  • 2 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q3 2024.

Based on New York Life Investment Management's 13F filing for Q3 2024, filed 7 Nov 2024.